Skip to main content

Table 3 Drugs used for rheumatoid arthritis treatment in the population of the REAL study [19]

From: Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study

Variables (n = 1116) n (%)
Glucocorticoids 529 (47.4)
 Dose ≥10 mg (n = 527) 82/527 (15.6)
Non-steroidal anti-inflammatory 743 (66.6)
Methotrexate 742 (66.5)
Leflunomide 378 (33.9)
Antimalarials (chloroquine/hydroxychloroquine) 146 (13.1)
Sulfasalazine 55 (4.9)
Tofacitinib 9 (0.8)
Biologicals 398 (35.7)
 Anti-TNF (adalimumab, infliximab, etanercept, certolizumab, golimumab) 222 (19.9)
 Anti-IL6r (tocilizumab) 55 (4.9)
 Abatacept 72 (6.5)
 Rituximab 49 (4.4)